News Tempus - Promo

Eli Lilly assures investors it can overcome the high-quality problem of too much demand

Eli Lilly‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply.

Source link

About The Author

Scroll to Top